




RealRate

PHARMACEUTICAL 2022

Sonoma Pharmaceuticals Inc
Rank 340 of 471



The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Sonoma Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 219% points.

The company's Economic Capital Ratio, given in the ranking table, is 203%, being 72% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	12,983
Cost of Goods Sold	12,070
Intangible Assets	0
Liabilities, Current	4,078
Liabilities, Non-Current	1,839
Other Assets	1,644
Other Compr. Net Income	1,031
Other Expenses	713
Other Liabilities	3,707
Other Net Income	212
Other Revenues	18,629
Property and Equipment	360
Research and Development	555
Selling, General and Administrative Expense	9,453

Output Variable	Value in 1000 USD
Assets	14,987
Liabilities	9,624
Expenses	22,791
Revenues	18,629
Stockholders Equity	5,363
Net Income	-3,950
Comprehensive Net Income	-3,434
BaseVar	33,637
ECR before Limited Liability	67%
Economic Capital Ratio	203%